Neion Bio Appoints John Maga as Head of Biologics and CMC

NEW YORK, Nov. 04, 2026 /CourierPR/ -- Neion Bio, a biotechnology company aiming to revolutionize the production of biologic medicines, has appointed John A. Maga, Ph.D., as Head of Biologics and CMC. With over 25 years of experience in biopharmaceutical development, Maga brings a wealth of expertise to Neion, including nearly 15 years at BioMarin Pharmaceutical, where he held senior leadership roles across analytical and process sciences.

Maga's extensive background includes leading development organizations at BioMarin, spanning a broad range of modalities such as oligonucleotides, gene therapies, recombinant proteins, monoclonal antibodies, peptides, and small molecules. His work at BioMarin involved steering technical and regulatory strategy behind two commercial approvals, alongside major regulatory filings and the growth of teams and capabilities across the CMC organization. He joined BioMarin in 2010 when the company acquired ZyStor Therapeutics, where he had spent the previous decade developing protein targeting technologies for lysosomal storage diseases and advancing the company's lead program to an open IND.

At Neion, Maga will lead biologics development and help expand the company’s capabilities to support partners co-developing complex and differentiated therapeutic proteins.

Neion's Raptor™ platform uses precision genetic engineering to produce recombinant proteins in the egg white of transgenic chickens. The platform is designed to enable extremely low cost production, scalable expansion through flock growth and limited capital requirements, while also taking advantage of the sophisticated protein processing capabilities of avian biology. The chicken oviduct is a highly specialized protein production organ, and the egg provides a large extracellular environment with low endogenous proteolytic activity. Together, these features create a highly capable production system that Neion believes can support a broad range of biologics, including programs where protein integrity, post-translational processing, or biological activity present particular development challenges.

Founded in 2024, Neion Bio is pioneering a new era in biomanufacturing, using frontier genetic engineering to harness nature’s most prolific molecular factory, the egg, to produce biological medicines with unprecedented efficiency, scalability, and environmental sustainability. The company aims to dramatically lower the cost of biologics manufacturing to spur biotech innovation and democratize global access to life-changing therapies. Neion’s Raptor™ platform enables localized, resilient domestic manufacturing of critical medicines, strengthening national security while unlocking significant commercial opportunities.